search
Back to results

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

Primary Purpose

Fibrodysplasia Ossificans Progressiva

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Palovarotene dose level 1
Palovarotene dose level 2
Palovarotene dose level 3
Palovarotene dose level 4
Sponsored by
Clementia Pharmaceuticals Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fibrodysplasia Ossificans Progressiva focused on measuring Open-label extension study, Clinical trial Phase 2, Efficacy and safety, Heterotopic ossification, Fibrodysplasia Ossificans Progressiva, Flare-up, Palovarotene, Retinoic acid receptor agonist, Retinoic acid receptor gamma agonist, Clementia, Myositis Ossificans Progressiva, Munchmeyer's Disease, FOP, Ipsen

Eligibility Criteria

6 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Completion of Study PVO-1A-202/Part B.
  • Written, signed, and dated informed consent and, for participants who are minors, age-appropriate participant assent (performed according to local regulations).
  • Accessible for treatment with palovarotene and follow-up (able and willing to travel to a site for the initial and all follow-up clinic visits).
  • Able to undergo low-dose, WBCT scan, excluding head.
  • Females of child-bearing potential must have a negative blood or urine pregnancy test (with sensitivity of at least 50 mIU/mL) prior to administration of palovarotene.
  • Male and FOCBP participants must agree to remain abstinent from heterosexual sex during treatment and for 1 month after treatment or, if sexually active, to use two effective methods of birth control during and for 1 month after treatment. Additionally, sexually active females of childbearing potential (FOCBP) participants must already be using two effective methods of birth control 1 month before treatment is to start. Specific risk of the use of retinoids during pregnancy, and the agreement to remain abstinent or use two effective methods of birth control will be clearly defined in the informed consent and the participant or legally authorized representatives.

Exclusion Criteria:

  • Any reason that, in the opinion of the Investigator, would lead to the inability of the participant and/or family to comply with the protocol.
  • Amylase or lipase >2x above the upper limit of normal or with a history of pancreatitis.
  • Elevated aspartate aminotransferase or alanine aminotransferase >2.5x the upper limit of normal.
  • Fasting triglycerides >400 mg/dL with or without therapy.
  • Currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, herbal preparations containing vitamin A or beta carotene, or fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.
  • Participants experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month as defined by the Columbia Suicide Severity Rating Scale (C-SSRS).

Sites / Locations

  • University of California San Francisco, Division of Endocrinology and Metabolism
  • Mayo Clinic, Department of Medicine
  • University of Pennsylvania, Center for FOP & Related Bone Disorders
  • Hospital Italiano de Buenos Aires, Department of Pediatrics
  • Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)
  • Hôpital Necker-Enfants Malades, Department of Genetics
  • The Royal National Orthopaedic Hospital, Brockley Hill

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Palovarotene dose level 1 (completed)

Palovarotene dose level 2

Palovarotene dose level 3

Palovarotene dose level 4

Arm Description

Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).

Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).

Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).

All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.

Outcomes

Primary Outcome Measures

Part A and Part B - Proportion of flare-up with no new HO ("responders")
Assessed by computed tomography (CT) scan (or plain radiographs for participants unable to undergo CT scan)
Part C - Annualized change in new HO volume
Assessed by low-dose whole body computed tomography (WBCT) (excluding head)

Secondary Outcome Measures

Part A - Proportion of participants across the seven HO scores (0-6)
Assessed by plain radiographs
Part A - Change from baseline in amount (area) of new heterotopic bone formed
Assessed by plain radiographs
Part A - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers
Part A and Part B - Change from baseline in active range of motion (ROM)
Assessed by goniometer
Part A and Part B - Change from baseline in ROM
Assessed by Cumulative Analogue Joint Involvement Scale (CAJIS)
Part A and Part B - Participant and Investigator global assessment of movement
Part A - Change from baseline in pain and swelling (for participants under 8 years of age)
Assessed by numeric rating scale (NRS) or Faces Pain Scale-Revised (FPS-R)
Part A and Part B - Change from baseline in physical function
Assessed by age-appropriate forms of the FOP-Physical Function Questionnaire (FOP-PFQ)
Part A and Part B - Change from baseline in physical and mental health
Assessed by age-appropriate forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale
Part A and Part B - Change from baseline in the use of assistive devices and adaptations for daily living by FOP participants
Part A and Part B - Presence of soft tissue swelling and/or cartilage
Assessed by magnetic resonance imaging (MRI) (or by US in participants unable to undergo MRI)
Part B - Change from baseline in amount of bone formation (volume)
Assessed by low-dose CT scan (or area by plain radiographs for participants unable to undergo CT scan)
Part B - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers
Duration of active, symptomatic flare-up (start date and end date)
Assessed by the participant and the Investigator
Part B (Chronic treatment) - Change from baseline in whole body burden of HO
Assessed by low-dose WBCT scan (excluding head)
Part B (Chronic treatment) - Number of flare-ups per participant-month overall, and by edema severity
Part C - Percent of participants with new HO
Part C - Change from baseline in ROM
Assessed by CAJIS
Part C - Change from baseline in physical function
Assessed by age-appropriate forms of the FOP-PFQ
Part C - Change from baseline in physical and mental function for participants ≥15 years old and mental function for participants <15 years old
Assessed by age-appropriate forms of the PROMIS Global Health Scale

Full Information

First Posted
October 26, 2014
Last Updated
October 11, 2022
Sponsor
Clementia Pharmaceuticals Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02279095
Brief Title
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Official Title
A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
October 27, 2014 (Actual)
Primary Completion Date
September 20, 2022 (Actual)
Study Completion Date
September 20, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clementia Pharmaceuticals Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO), i.e., abnormal bone formation, often associated with painful, recurrent episodes of soft tissue swelling (flare-ups). Lesions begin in early childhood and lead to progressive ankyloses of major joints with resultant loss of movement. In this study, the ability of different palovarotene dosing regimens to prevent the formation of new HO will be evaluated in adult and pediatric participants with FOP.
Detailed Description
The main objective of this Phase 2, multicenter, open-label study is to evaluate the safety and efficacy of different palovarotene dosing regimens in participants with FOP. Efficacy will be assessed based on the ability of palovarotene to prevent the formation of new heterotopic ossification (HO) as assessed by low-dose whole body computed tomography (WBCT) scan, excluding head. The study was divided into four parts: Part A (completed on July 2017), Part B (completed on October 2018), Part C (completed) and Part D (completd). Each part was associated with revised palovarotene treatment regimens. In Part A, all pediatric and adult participants who successfully completed Study PVO-1A-201 were enrolled and followed for up to 36 months. Participants who had an eligible flare-up received 10 mg palovarotene daily for 14 days, followed by 5 mg palovarotene daily for 28 days (or weight-based equivalent). In Part B, participants who successfully completed Study PVO-1A-201 (including any participant who participated in Part A of Study PVO-1A-202) as well as up to 20 new adult participants were followed for up to 24 months. The Adult Cohort included all participants with at least 90% skeletal maturity, regardless of age. The Pediatric Cohort included all participants with less than 90% skeletal maturity. Any Pediatric Cohort participant who achieved ≥90% skeletal maturity during Part B was considered for enrollment into the Adult Cohort at the discretion of the Investigator. Part B added a 5 mg palovarotene daily chronic treatment regimen administered between flare-ups for participants in the Adult Cohort for up to 24 months. Part B also increased the flare-up dosing to 20 mg palovarotene daily for 28 days, followed by 10 mg palovarotene daily for 56 days (or weight-adjusted equivalents in the Pediatric Cohort). Treatment could be extended if the flare-up was still ongoing. In Part C, participants from Part B are being followed for up to an additional 48 months. There will be no new participants in Part C. All eligible participants, including skeletally immature participants, are receiving 5 mg palovarotene daily chronic treatment regimen (weight-adjusted doses for skeletally immature participants). In Part D, annual post last dose of study treatment assessments for up to 2 years will be obtained in participants who were skeletally immature at the time of study treatment discontinuation in order to obtain longer-term safety data. No new participants will be enrolled into Part D. Part C plus Part D duration will not exceed 48 months. All participants will undergo all study procedures as specified in the respective schedule of assessments and for as long as they are not 100% skeletally mature.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibrodysplasia Ossificans Progressiva
Keywords
Open-label extension study, Clinical trial Phase 2, Efficacy and safety, Heterotopic ossification, Fibrodysplasia Ossificans Progressiva, Flare-up, Palovarotene, Retinoic acid receptor agonist, Retinoic acid receptor gamma agonist, Clementia, Myositis Ossificans Progressiva, Munchmeyer's Disease, FOP, Ipsen

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Palovarotene dose level 1 (completed)
Arm Type
Experimental
Arm Description
Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).
Arm Title
Palovarotene dose level 2
Arm Type
Experimental
Arm Description
Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
Arm Title
Palovarotene dose level 3
Arm Type
Experimental
Arm Description
Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
Arm Title
Palovarotene dose level 4
Arm Type
Experimental
Arm Description
All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
Intervention Type
Drug
Intervention Name(s)
Palovarotene dose level 1
Intervention Description
Palovarotene was taken orally once daily at approximately the same time each day.
Intervention Type
Drug
Intervention Name(s)
Palovarotene dose level 2
Intervention Description
Palovarotene will be taken orally once daily at approximately the same time each day.
Intervention Type
Drug
Intervention Name(s)
Palovarotene dose level 3
Intervention Description
Palovarotene will be taken orally once daily at approximately the same time each day.
Intervention Type
Drug
Intervention Name(s)
Palovarotene dose level 4
Intervention Description
Palovarotene will be taken orally once daily at approximately the same time each day.
Primary Outcome Measure Information:
Title
Part A and Part B - Proportion of flare-up with no new HO ("responders")
Description
Assessed by computed tomography (CT) scan (or plain radiographs for participants unable to undergo CT scan)
Time Frame
Week 12
Title
Part C - Annualized change in new HO volume
Description
Assessed by low-dose whole body computed tomography (WBCT) (excluding head)
Time Frame
Every 12 months for up to 72 months
Secondary Outcome Measure Information:
Title
Part A - Proportion of participants across the seven HO scores (0-6)
Description
Assessed by plain radiographs
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Title
Part A - Change from baseline in amount (area) of new heterotopic bone formed
Description
Assessed by plain radiographs
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Title
Part A - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, and 12 (Flare-up Component)
Title
Part A and Part B - Change from baseline in active range of motion (ROM)
Description
Assessed by goniometer
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Title
Part A and Part B - Change from baseline in ROM
Description
Assessed by Cumulative Analogue Joint Involvement Scale (CAJIS)
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Title
Part A and Part B - Participant and Investigator global assessment of movement
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Title
Part A - Change from baseline in pain and swelling (for participants under 8 years of age)
Description
Assessed by numeric rating scale (NRS) or Faces Pain Scale-Revised (FPS-R)
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 9, and 12 (Flare-up Component)
Title
Part A and Part B - Change from baseline in physical function
Description
Assessed by age-appropriate forms of the FOP-Physical Function Questionnaire (FOP-PFQ)
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 8, 9, and 12 (Flare-up Component)
Title
Part A and Part B - Change from baseline in physical and mental health
Description
Assessed by age-appropriate forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 8, 9, and 12 (Flare-up Component)
Title
Part A and Part B - Change from baseline in the use of assistive devices and adaptations for daily living by FOP participants
Time Frame
Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Title
Part A and Part B - Presence of soft tissue swelling and/or cartilage
Description
Assessed by magnetic resonance imaging (MRI) (or by US in participants unable to undergo MRI)
Time Frame
Flare-up Weeks 6 and 12 (Flare-up Component)
Title
Part B - Change from baseline in amount of bone formation (volume)
Description
Assessed by low-dose CT scan (or area by plain radiographs for participants unable to undergo CT scan)
Time Frame
Flare-up Week 12
Title
Part B - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers
Time Frame
Flare-up Weeks 4, 8, and 12
Title
Duration of active, symptomatic flare-up (start date and end date)
Description
Assessed by the participant and the Investigator
Time Frame
Up to 12 weeks
Title
Part B (Chronic treatment) - Change from baseline in whole body burden of HO
Description
Assessed by low-dose WBCT scan (excluding head)
Time Frame
Study Months 12 and 24
Title
Part B (Chronic treatment) - Number of flare-ups per participant-month overall, and by edema severity
Time Frame
Up to 24 months
Title
Part C - Percent of participants with new HO
Time Frame
Every 12 months up to 72 months
Title
Part C - Change from baseline in ROM
Description
Assessed by CAJIS
Time Frame
Every 6 months up to 72 months
Title
Part C - Change from baseline in physical function
Description
Assessed by age-appropriate forms of the FOP-PFQ
Time Frame
Every 6 months up to 72 months
Title
Part C - Change from baseline in physical and mental function for participants ≥15 years old and mental function for participants <15 years old
Description
Assessed by age-appropriate forms of the PROMIS Global Health Scale
Time Frame
Every 6 months up to 72 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Completion of Study PVO-1A-202/Part B. Written, signed, and dated informed consent and, for participants who are minors, age-appropriate participant assent (performed according to local regulations). Accessible for treatment with palovarotene and follow-up (able and willing to travel to a site for the initial and all follow-up clinic visits). Able to undergo low-dose, WBCT scan, excluding head. Females of child-bearing potential must have a negative blood or urine pregnancy test (with sensitivity of at least 50 mIU/mL) prior to administration of palovarotene. Male and FOCBP participants must agree to remain abstinent from heterosexual sex during treatment and for 1 month after treatment or, if sexually active, to use two effective methods of birth control during and for 1 month after treatment. Additionally, sexually active females of childbearing potential (FOCBP) participants must already be using two effective methods of birth control 1 month before treatment is to start. Specific risk of the use of retinoids during pregnancy, and the agreement to remain abstinent or use two effective methods of birth control will be clearly defined in the informed consent and the participant or legally authorized representatives. Exclusion Criteria: Any reason that, in the opinion of the Investigator, would lead to the inability of the participant and/or family to comply with the protocol. Amylase or lipase >2x above the upper limit of normal or with a history of pancreatitis. Elevated aspartate aminotransferase or alanine aminotransferase >2.5x the upper limit of normal. Fasting triglycerides >400 mg/dL with or without therapy. Currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, herbal preparations containing vitamin A or beta carotene, or fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment. Participants experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month as defined by the Columbia Suicide Severity Rating Scale (C-SSRS).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ipsen Medical Director
Organizational Affiliation
Ipsen
Official's Role
Study Director
Facility Information:
Facility Name
University of California San Francisco, Division of Endocrinology and Metabolism
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Mayo Clinic, Department of Medicine
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
University of Pennsylvania, Center for FOP & Related Bone Disorders
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Hospital Italiano de Buenos Aires, Department of Pediatrics
City
Buenos Aires
Country
Argentina
Facility Name
Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Facility Name
Hôpital Necker-Enfants Malades, Department of Genetics
City
Paris
Country
France
Facility Name
The Royal National Orthopaedic Hospital, Brockley Hill
City
Stanmore
State/Province
Middlesex
ZIP/Postal Code
HA7 4LP
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21460849
Citation
Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum In: Nat Med. 2012 Oct;18(10):1592.
Results Reference
background
Links:
URL
http://ifopa.org
Description
Website for the International FOP Association
URL
http://fopfrance.fr
Description
Website for the French FOP Association
URL
http://clementiapharma.com/
Description
Click here for more information about this study: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FOP)

Learn more about this trial

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

We'll reach out to this number within 24 hrs